52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Cardinal Health Provides Fiscal Year 2022 Financial Update
Clarity Pharmaceuticals Says Co And Cardinal Health Enter Into Agreement For Targeted Copper Theranostics
Cardinal Health Inc- Sees Low-Double Digit Percentage Growth For Pharma Segment Revenue In FY22
Cardinal Health, Inc. is a healthcare services and products company. The Company operates through two segments: Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, over-the-counter healthcare and consumer products. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals; and repackages generic pharmaceuticals and over-the-counter healthcare products. The Medical segment manufactures, sources and distributes a range of medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. This segment also distributes a range of national brand products and provides supply chain services and solutions to hospitals and other healthcare providers.
Biotechnology & Drugs
7000 Cardinal Pl
Gregory B. Kenny
Independent Non-Executive Chairman of the Board
Michael C. Kaufmann
Chief Executive Officer, Director
Jason M. Hollar
Chief Financial Officer
Victor L. Crawford
Chief Executive Officer - Pharmaceutical Segment
Stephen M. Mason
Chief Executive Officer - Medical Segment
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
U.S. cities and counties have embraced a proposed settlement worth up to $26 billion resolving lawsuits alleging three large drug distributors and drugmaker Johnson & Johnson fueled the U.S. opioid epidemic, lawyers behind the deal said on Wednesday, increasing the odds...
Rhode Island on Tuesday reversed course and threw its support behind a $21 billion nationwide settlement it originally declined to back resolving lawsuits alleging that three large drug distributors fueled the deadly U.S. opioid epidemic.
Johnson & Johnson on Friday said it had agreed to pay $44 million to resolve claims that it fueled the opioid epidemic in New Mexico, a state which originally opted against participating in a nationwide settlement resolving thousands of similar cases.
The state of Georgia has decided to join a proposed $26 billion nationwide settlement resolving lawsuits alleging that three large drug distributors and drugmaker Johnson & Johnson fueled the deadly U.S. opioid epidemic.
Nevada has agreed to back a proposed nationwide settlement worth up to $26 billion resolving lawsuits against three large drug distributors and the drugmaker Johnson & Johnson over the deadly U.S. opioid epidemic, the state's attorney general said on Tuesday.
Drug distributors McKesson Corp, AmerisourceBergen Corp and Cardinal Health Inc said on Wednesday the deadline for U.S. state subdivisions to join an opioid settlement agreement has been extended to Jan. 26 from Jan. 2.
The U.S. Food and Drug Administration on Friday classified the recall of some of Cardinal Health Inc's devices, which are used to insert umbilical vein catheters in infants, as the most serious type of recall after two reports of death.
A group of state attorneys general unveiled on Wednesday a landmark $26 billion settlement with large drug companies for allegedly fueling the deadly nationwide opioid epidemic, but the deal still requires support from thousands of local governments.
The three largest U.S. drug distributors, facing their first trial over claims that they fueled the opioid crisis, said responsibility for ballooning painkiller sales lies with doctors, drugmakers and regulators.
The three largest U.S. drug distributors are facing trial on Monday in West Virginia in a lawsuit accusing them of fueling the opioid crisis that has resulted in 500,000 overdose deaths in the United States over two decades.
The nation's "Big Three" leading drug distributors have failed to escape a lawsuit by the city of Huntington, West Virginia, and its county seeking to hold them liable for harms caused by the opioid epidemic.
Cardinal Health Inc will sell its Cordis medical device business to private equity firm Hellman & Friedman in a deal valued at about $1 billion, the drug distributor said on Friday.
Drug distributor Cardinal Health Inc said on Friday it would sell its Cordis medical device business to private equity firm Hellman & Friedman in a deal valued at about $1 billion. (Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila)
* DAVE EVANS TO JOIN CARDINAL HEALTH BOARD OF DIRECTORS Source text for Eikon: Further company coverage:
Robbins Geller Rudman & Dowd has beat out two other top plaintiffs firms for the job of lead counsel in a proposed class action alleging Cardinal Health Inc misled investors about problems at a medical device maker it bought.
* CARDINAL HEALTH INC - SENDING IRREVOCABLE NOTICE OF EARLY REDEMPTION TO HOLDERS OF CO'S $500 MILLION 4.625% NOTES DUE 2020
* CARDINAL HEALTH - SEES MID-SINGLE DIGIT PERCENTAGE DECLINE IN 2020 PHARMACEUTICAL SEGMENT PROFIT - PRESENTATION Source text for Eikon: Further company coverage:
* CARDINAL HEALTH REPORTS THIRD QUARTER RESULTS FOR FISCAL YEAR 2020
* CARDINAL HEALTH - JASON HOLLAR WILL RECEIVE A BASE SALARY OF $700,000 Source text for Eikon: https://bit.ly/2IYvLGH Further company coverage:
* CARDINAL HEALTH NAMES JASON HOLLAR AS NEW CHIEF FINANCIAL OFFICER
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.